METTL3 and neoplasm: A study by Yu et al. found that Mettl3 was correlated with the expression level of immune checkpoints; and it revealed that in mice, Mettl3 inhibitors combined with anti-PD-1 therapy could slow down tumor progression (Yu et al., 2022).